MA47420A - Composés inhibiteurs d'oga - Google Patents
Composés inhibiteurs d'ogaInfo
- Publication number
- MA47420A MA47420A MA047420A MA47420A MA47420A MA 47420 A MA47420 A MA 47420A MA 047420 A MA047420 A MA 047420A MA 47420 A MA47420 A MA 47420A MA 47420 A MA47420 A MA 47420A
- Authority
- MA
- Morocco
- Prior art keywords
- inhibitor compounds
- oga inhibitor
- oga
- compounds
- inhibitor
- Prior art date
Links
- 229940126137 O-GlcNAcase inhibitor Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17154751 | 2017-02-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA47420A true MA47420A (fr) | 2019-12-11 |
Family
ID=57965815
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA047420A MA47420A (fr) | 2017-02-06 | 2018-02-06 | Composés inhibiteurs d'oga |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20200048267A1 (fr) |
| EP (1) | EP3577121A1 (fr) |
| JP (1) | JP2020506940A (fr) |
| CN (1) | CN110267961A (fr) |
| AU (1) | AU2018216040A1 (fr) |
| CA (1) | CA3045816A1 (fr) |
| MA (1) | MA47420A (fr) |
| WO (1) | WO2018141984A1 (fr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3868752A1 (fr) | 2014-08-28 | 2021-08-25 | Asceneuron SA | Inhibiteurs de la glycosidase |
| SG11201807012QA (en) | 2016-02-25 | 2018-09-27 | Asceneuron S A | Acid addition salts of piperazine derivatives |
| AU2017222958B2 (en) | 2016-02-25 | 2019-07-18 | Asceneuron S. A. | Glycosidase inhibitors |
| CN108884078A (zh) | 2016-02-25 | 2018-11-23 | 阿森纽荣股份公司 | 糖苷酶抑制剂 |
| US11261183B2 (en) | 2016-02-25 | 2022-03-01 | Asceneuron Sa | Sulfoximine glycosidase inhibitors |
| WO2018154133A1 (fr) * | 2017-02-27 | 2018-08-30 | Janssen Pharmaceutica Nv | Dérivés de [1,2,4]-triazolo [1,5-a]-pyrimidinyle substitués par de la pipéridine, de la morpholine ou de la pipérazine utilisés en tant qu'inhibiteurs d'oga |
| WO2019037860A1 (fr) | 2017-08-24 | 2019-02-28 | Asceneuron S.A. | Inhibiteurs linéaires de la glycosidase |
| WO2020039027A1 (fr) | 2018-08-22 | 2020-02-27 | Asceneuron S. A. | Inhibiteurs de pyrrolidine glycosidase |
| WO2020039029A1 (fr) * | 2018-08-22 | 2020-02-27 | Asceneuron S. A. | Composés spiro utilisés en tant qu'inhibiteurs de glycosidases |
| IL280841B2 (en) | 2018-08-22 | 2024-12-01 | Asceneuron S A | Succinate and fumarate acid addition salts of piperazine derivatives useful as glycosidase inhibitors |
| WO2020039028A1 (fr) | 2018-08-22 | 2020-02-27 | Asceneuron S. A. | Inhibiteurs de tétrahydro-benzoazépine glycosidase |
| AR120324A1 (es) * | 2019-10-29 | 2022-02-09 | Biogen Ma Inc | Inhibidores de o-glucoproteína-2-acetamido-2-deoxi-3-d-glucopiranosidasa espirocíclica |
| WO2025247394A1 (fr) * | 2024-05-31 | 2025-12-04 | 纽欧申医药(上海)有限公司 | Composé hétérocyclique contenant de l'azote, composition pharmaceutique de celui-ci et utilisation associée |
| WO2026021588A1 (fr) * | 2024-07-26 | 2026-01-29 | 浙江同源康医药股份有限公司 | Inhibiteur d'oga et son utilisation |
| CN119569746B (zh) * | 2025-02-06 | 2025-05-13 | 纽欧申医药(上海)有限公司 | 含氮杂环化合物、其药物组合物及应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1519939T5 (da) | 2002-07-05 | 2011-01-24 | Targacept Inc | N-Aryl-diazaspirocykliske forbindelser og fremgangsmåder til fremstilling og anvendelse deraf |
| JPWO2009154132A1 (ja) * | 2008-06-19 | 2011-12-01 | Ｍｓｄ株式会社 | スピロジアミン−ジアリールケトオキシム誘導体 |
| TW201030007A (en) | 2009-02-06 | 2010-08-16 | Gruenenthal Gmbh | Substituted spiro-amides as b1r modulators |
| US20120010186A1 (en) * | 2009-03-23 | 2012-01-12 | Merck Frosst Canada Ltd. | Heterocyclic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| US9221809B2 (en) | 2011-10-31 | 2015-12-29 | Merck Sharp & Dohme Corp. | Aminopyrimidinones as interleukin receptor-associated kinase inhibitors |
| WO2014023723A1 (fr) | 2012-08-08 | 2014-02-13 | Novartis Ag | Azines substituées comme pesticides |
| WO2016015605A1 (fr) * | 2014-07-26 | 2016-02-04 | Sunshine Lake Pharma Co., Ltd. | Composés en tant que petites molécules inhibitrices de la cdk et leurs utilisations |
| EP3868752A1 (fr) * | 2014-08-28 | 2021-08-25 | Asceneuron SA | Inhibiteurs de la glycosidase |
| BR112017028318B1 (pt) * | 2015-07-02 | 2024-02-20 | Janssen Sciences Ireland Uc | Composto antibacteriano, seu uso, processo para sua preparação,produto que o contém, composição farmacêutica e combinação |
| WO2017087858A1 (fr) * | 2015-11-20 | 2017-05-26 | Abide Therapeutics, Inc. | Composés de pyrazole, procédés de production et utilisation |
| WO2017087863A1 (fr) * | 2015-11-20 | 2017-05-26 | Abide Therapeutics, Inc. | Composés de pyrazole, procédés de production et utilisation |
| US11186564B2 (en) * | 2016-08-04 | 2021-11-30 | Sunovion Pharmaceuticals Inc. | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders |
-
2018
- 2018-02-06 AU AU2018216040A patent/AU2018216040A1/en not_active Abandoned
- 2018-02-06 EP EP18705346.7A patent/EP3577121A1/fr not_active Withdrawn
- 2018-02-06 WO PCT/EP2018/052901 patent/WO2018141984A1/fr not_active Ceased
- 2018-02-06 US US16/482,327 patent/US20200048267A1/en not_active Abandoned
- 2018-02-06 CN CN201880010260.3A patent/CN110267961A/zh active Pending
- 2018-02-06 CA CA3045816A patent/CA3045816A1/fr not_active Abandoned
- 2018-02-06 MA MA047420A patent/MA47420A/fr unknown
- 2018-02-06 JP JP2019542375A patent/JP2020506940A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3045816A1 (fr) | 2018-08-09 |
| CN110267961A (zh) | 2019-09-20 |
| JP2020506940A (ja) | 2020-03-05 |
| AU2018216040A1 (en) | 2019-06-20 |
| WO2018141984A1 (fr) | 2018-08-09 |
| US20200048267A1 (en) | 2020-02-13 |
| EP3577121A1 (fr) | 2019-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA52939A (fr) | Composés inhibiteurs d'oga | |
| MA47575A (fr) | Composés inhibiteurs d'oga monocyclique | |
| MA47420A (fr) | Composés inhibiteurs d'oga | |
| MA52942A (fr) | Composés inhibiteurs d'oga | |
| MA47576A (fr) | Composés inhibiteurs d'oga bicyclique | |
| EP3720430A4 (fr) | Composés benzocarbonyle | |
| EP3836923A4 (fr) | Composés pyrrolo-dipyridine | |
| MA52948A (fr) | Composés | |
| EP3464275A4 (fr) | Composés inhibiteurs de l'egfr | |
| MA51669A (fr) | Composés | |
| EP3740487A4 (fr) | Composés benzamide | |
| DK3497103T3 (da) | Pyridopyrimdinon-cdk2/4/6-inhibitorer | |
| MA44725A (fr) | Formulations d'un inhibiteur de lsd1 | |
| MA53003A (fr) | Composés | |
| MA52004A (fr) | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase | |
| MA49006A (fr) | Inhibiteurs d'ip6k | |
| EP3562487A4 (fr) | Composés inhibiteurs des métalloenzymes | |
| EP3728289A4 (fr) | Composés optimisés | |
| EP3464336A4 (fr) | Composés | |
| MA52946A (fr) | Composés | |
| EP3808747A4 (fr) | Composé d'imidazopyridinone | |
| MA53648A (fr) | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glucopyranosidase | |
| IL269695A (en) | Compounds useful as inhibitors of alcat 1 | |
| LT3867247T (lt) | Naujieji junginiai | |
| EP3713941A4 (fr) | Composés de pyrazolopyridinone |